MedTrace Logo

Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

NCT00296387 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1160

Last updated 2007-12-17

No results posted yet for this study

Summary

The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is beneficial compared to placebo.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Rosuvastatin

DRUG

Atorvastatin

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca France Medical Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Completion
2007-10-31

Countries

  • Belgium
  • Canada
  • Estonia
  • France
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Portugal
  • Spain
  • Tunisia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00296387 on ClinicalTrials.gov